Artistic rendition of gene editing tools embedded in a model of DNA double helix

Collaborating as partners to accelerate your research

Gene editing technologies are becoming increasingly important for research and applied uses. Many of our genome editing technologies, including both TAL effectors and CRISPR-Cas9 systems, are available under license for use in a variety of commercial applications, including research services, contract manufacturing services, therapeutics and therapeutic bioproduction, vaccines, diagnostics, animal health, biofuels, and quality assurance/quality control.

Submit an inquiry below to discuss how we might work together.

Submit an inquiry    Discover our genome editing tools

Licensing opportunities

TALXcell genome editing platform

Easy-to-use, flexible technology to accelerate your genome editing projects

With over a decade of experience in developing innovative tools for genome editing, we have designed a novel, programmable TAL-based enzyme, Invitrogen TALXcell nuclease, for use in therapeutic development for CAR-T, NK and allogenic (iPSC) targets. The TALXcell platform has comparable performance as CRISPR-Cas9, but without some of the common limitations of that system.

The TALXcell nuclease consists of a DNA binding domain that is specifically engineered to target your site of interest and that is fused with a highly effective nuclease to cleave the DNA.

Improved performance

  • Flexible platform—broad application across cell types, delivery systems (e.g., mRNA or protein), and therapeutic areas, allowing you to optimize the nuclease to your needs
  • Edit anywhere in the genome—as TALXcell nuclease does not have sequence-specific requirements, the nuclease enables you to edit anywhere in the genome
  • High editing efficiency—the performance of TALXcell nuclease is comparable to other editing platforms such as CRISPR-Cas9 (Figure 1) over a range of different model systems, making it attractive for your genome editing projects:
    • T cells: up to 95% editing efficiency
    • NK cells: up to 64% editing efficiency
    • iPSCs: up to 63% editing efficiency
Figure 1. Human primary T cell TCR KO efficiency. TALXcell nuclease (94.9%) has same TCR KO efficiency compared to CRISPR-Cas9 (94.7%). Surface T cell receptor measured by flow cytometry.

Enablement

  • Single-party licensing—Thermo Fisher Scientific owns or controls the foundational intellectual property (IP) for the TALXcell nuclease technology, (nonexclusive and exclusive licenses are available)
  • Strategic partnership—Thermo Fisher Scientific offers research tools and reagents to support your genome editing projects from initial discovery through preclinical studies

To discuss commercial opportunities with our TALXcell genome editing platform, please contact us at outlicensing@thermofisher.com.

TAL effectors for applied markets

Conceptual image of a custom designed TAL protein interacting at the molecular level with a double-stranded DNA

GeneArt TALs provide custom DNA-binding proteins for accurate DNA targeting and precise gene editing and gene regulation, enabling users to target any locus in the genome.

The Thermo Fisher Scientific team has clarified a path for users to move confidently forward with GeneArt TALs in research and applied markets, by compiling a powerful intellectual property (IP) portfolio that includes not only the foundational IP originating from the University of Minnesota, Iowa State University, and Martin-Luther-Universitat Halle-Wittenberg, but also IP originating from Thermo Fisher Scientific, Cellectis AS, and others.

Commercial licensing under this broad IP portfolio is available for most applied uses, including transgenic animal services, animal health, quality assurance/quality control, and production of biological materials, chemicals, and compounds for uses in a diverse range of applications.

Please contact us at outlicensing@thermofisher.com or visit TAL-Based Genome Editing to learn more.

CRISPR-Cas9 system

Artistic rendition of engineered CRISPR-Cas9 complex interacting with its target gene sequence

The simplicity and flexibility of Invitrogen CRISPR-Cas9 systems are revolutionizing the field of genome editing. Learn more about CRISPR-Based Genome Editing

To discuss commercial opportunities with our CRISPR-Cas products, please contact us at outlicensing@thermofisher.com.

RNA interference (RNAi)

Artistic rendition of blue print overlaid on petals of a flower (an early model organism for RNAi)

RNAi has proven to be a specific, potent and highly successful approach for loss-of-function studies in virtually all eukaryotic organisms. We offer Stealth RNAi technology for all research applications and additionally for commercial uses, including therapeutics, in conjunction with a commercial use license from Thermo Fisher Scientific. Stealth RNAi technology utilizes a proprietary structure, which uses modified chemical bases in a unique 25-base format. Learn more about RNAi

To discuss commercial opportunities with our RNAi products, please contact us at outlicensing@thermofisher.com.

TALXcell genome editing platform

Easy-to-use, flexible technology to accelerate your genome editing projects

With over a decade of experience in developing innovative tools for genome editing, we have designed a novel, programmable TAL-based enzyme, Invitrogen TALXcell nuclease, for use in therapeutic development for CAR-T, NK and allogenic (iPSC) targets. The TALXcell platform has comparable performance as CRISPR-Cas9, but without some of the common limitations of that system.

The TALXcell nuclease consists of a DNA binding domain that is specifically engineered to target your site of interest and that is fused with a highly effective nuclease to cleave the DNA.

Improved performance

  • Flexible platform—broad application across cell types, delivery systems (e.g., mRNA or protein), and therapeutic areas, allowing you to optimize the nuclease to your needs
  • Edit anywhere in the genome—as TALXcell nuclease does not have sequence-specific requirements, the nuclease enables you to edit anywhere in the genome
  • High editing efficiency—the performance of TALXcell nuclease is comparable to other editing platforms such as CRISPR-Cas9 (Figure 1) over a range of different model systems, making it attractive for your genome editing projects:
    • T cells: up to 95% editing efficiency
    • NK cells: up to 64% editing efficiency
    • iPSCs: up to 63% editing efficiency
Figure 1. Human primary T cell TCR KO efficiency. TALXcell nuclease (94.9%) has same TCR KO efficiency compared to CRISPR-Cas9 (94.7%). Surface T cell receptor measured by flow cytometry.

Enablement

  • Single-party licensing—Thermo Fisher Scientific owns or controls the foundational intellectual property (IP) for the TALXcell nuclease technology, (nonexclusive and exclusive licenses are available)
  • Strategic partnership—Thermo Fisher Scientific offers research tools and reagents to support your genome editing projects from initial discovery through preclinical studies

To discuss commercial opportunities with our TALXcell genome editing platform, please contact us at outlicensing@thermofisher.com.

TAL effectors for applied markets

Conceptual image of a custom designed TAL protein interacting at the molecular level with a double-stranded DNA

GeneArt TALs provide custom DNA-binding proteins for accurate DNA targeting and precise gene editing and gene regulation, enabling users to target any locus in the genome.

The Thermo Fisher Scientific team has clarified a path for users to move confidently forward with GeneArt TALs in research and applied markets, by compiling a powerful intellectual property (IP) portfolio that includes not only the foundational IP originating from the University of Minnesota, Iowa State University, and Martin-Luther-Universitat Halle-Wittenberg, but also IP originating from Thermo Fisher Scientific, Cellectis AS, and others.

Commercial licensing under this broad IP portfolio is available for most applied uses, including transgenic animal services, animal health, quality assurance/quality control, and production of biological materials, chemicals, and compounds for uses in a diverse range of applications.

Please contact us at outlicensing@thermofisher.com or visit TAL-Based Genome Editing to learn more.

CRISPR-Cas9 system

Artistic rendition of engineered CRISPR-Cas9 complex interacting with its target gene sequence

The simplicity and flexibility of Invitrogen CRISPR-Cas9 systems are revolutionizing the field of genome editing. Learn more about CRISPR-Based Genome Editing

To discuss commercial opportunities with our CRISPR-Cas products, please contact us at outlicensing@thermofisher.com.

RNA interference (RNAi)

Artistic rendition of blue print overlaid on petals of a flower (an early model organism for RNAi)

RNAi has proven to be a specific, potent and highly successful approach for loss-of-function studies in virtually all eukaryotic organisms. We offer Stealth RNAi technology for all research applications and additionally for commercial uses, including therapeutics, in conjunction with a commercial use license from Thermo Fisher Scientific. Stealth RNAi technology utilizes a proprietary structure, which uses modified chemical bases in a unique 25-base format. Learn more about RNAi

To discuss commercial opportunities with our RNAi products, please contact us at outlicensing@thermofisher.com.

For Research Use Only. Not for use in diagnostic procedures.
UX DATA-TRKR Retired - Admins, feel free to remove this reference component.